Alison C. Finger
About Alison C. Finger
Alison C. Finger (age 61) is an independent Class I director of ADMA Biologics, serving since 2023. She sits on the Compensation Committee and the Governance and Nominations Committee, and the Board has determined she is independent under Nasdaq standards. Finger has 30+ years of biotech/pharma leadership across gene medicine, cell therapy, oncology, neurology, virology, and metabolics; she holds a B.A. from St. Lawrence University and an M.B.A. from Duke University’s Fuqua School of Business .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Vicero, Inc. | Chief Operating Officer | Sep 2023–present | Leads business operations, strategic and financial planning, company build, BD |
| bluebird bio, Inc. | Chief Commercial Officer | Aug 2015–Jan 2021 | Built commercial enterprise in US/EU; prepared first gene/cell therapy products for market |
| Bristol-Myers Squibb (BMS) | Senior commercial leadership; Managing Director Australia/NZ | May 2009–May 2014 | Led virology, neurology, hematology/oncology franchises; global commercialization; country/regional/global P&L management |
External Roles
| Organization | Role | Tenure | Committee Roles/Notes |
|---|---|---|---|
| KeifeRx LLC | Independent Director | Current | — |
| Decibel Therapeutics (Nasdaq: DBTX) | Independent Director | Dec 2021–Sep 2023 (acquired) | Chair of Nominating & Corporate Governance; Audit Committee member |
| VBL Therapeutics (Nasdaq: VBLT) | Independent Director | Jul 2021–Aug 2022 | — |
| Alliance for Regenerative Medicine | Chair, Gene Therapy Section; Foundation Board member | Prior | Sector leadership and advocacy roles |
Board Governance
- Committee assignments: Compensation Committee member; Governance & Nominations Committee member; not on Audit. Committee chairs are Young T. Kwon (Compensation), Lawrence P. Guiheen (Governance), and Young T. Kwon (Audit) .
- Independence: Board determined Finger is independent under Nasdaq listing standards .
- Attendance: Board met 5 times in FY2024; no director attended fewer than 75% of Board and applicable committee meetings. Directors were encouraged to attend the annual meeting, and each then-serving director (except former director Bryant Fong) attended June 4, 2024 .
- Engagement: Compensation Committee met 7 times; Audit 6 times; Governance & Nominations 1 time in FY2024, indicating active committee oversight cadence .
- Interlocks/conflicts: Finger joined the Compensation Committee on Nov 19, 2024 following Mr. Fong’s resignation; no compensation committee interlocks or insider participation were disclosed for FY2024 .
Fixed Compensation
| Component | Amount | Detail |
|---|---|---|
| Fees Earned or Paid in Cash (2024) | $51,578 | Reflects Board retainer and committee/membership fees earned in 2024 |
| Director Cash Fee Policy (2023–2024) | Board retainer: $50,000; Committee Chair retainers: Audit $22,250, Compensation $16,500, Governance $11,000; Committee member retainers: Audit $11,125, Compensation $8,250, Governance $5,500; 25% of annual Board/Committee fees paid quarterly | Company-wide policy applicable during 2023–2024 |
Performance Compensation
| Equity Award | Grant Date | Quantity | Fair Value/Exercise | Vesting/Expiration | Notes |
|---|---|---|---|---|---|
| RSUs (annual) | Feb 26, 2024 | 24,040 | $129,816 total (at $5.40 close) | Vest in two equal installments at 6 and 12 months; fully vested at 1 year | Granted to each non-employee director; subject to continued service |
| Stock Options (annual) | Feb 26, 2024 | 37,541 | $5.40 strike | Vest monthly over 12 months; expire earlier of Feb 26, 2034 or first anniversary after service ends | Granted to each non-employee director |
| Options Outstanding (aggregate) | As of Dec 31, 2024 | 136,411 | — | — | Finger’s total option count (vested + unvested) at year-end |
| Total 2024 Equity Compensation | — | — | RSUs: $129,816; Options: $124,583 | — | Mix indicates equity-heavy director pay |
- Compensation Mix (2024): Cash $51,578 (≈17%); RSUs $129,816 + Options $124,583 (≈83% equity) of total $305,977, reinforcing ownership alignment .
Other Directorships & Interlocks
| Issue | Disclosure |
|---|---|
| Compensation Committee interlocks | None in FY2024; Finger appointed Nov 19, 2024; no member was a company officer |
| Designated nominees on ADMA Board | Aisling Capital (Elms) and Hariden LLC (Jerrold Grossman) have nominating rights while maintaining holdings from 2012 financing; Finger is not a designee, supporting independence |
Expertise & Qualifications
- Domain expertise: Commercial leadership in gene/cell therapy; plasma/biopharma commercialization; global market launches. Served as bluebird bio CCO and BMS franchise/country leader .
- Governance credentials: Chaired Nominating & Corporate Governance and served on Audit at Decibel Therapeutics; current ADMA committee roles align with experience .
- Education: B.A., St. Lawrence University; M.B.A., Duke Fuqua .
Equity Ownership
| Measure | Amount | Breakdown/Notes |
|---|---|---|
| Total Beneficial Ownership (Mar 31, 2025) | 164,520 shares; <1% | Includes 140,480 options exercisable or vesting within 60 days and 24,040 shares directly owned |
| Direct Shares | 24,040 | Held directly by Finger |
| Options – Exercisable within 60 days | 140,480 | Counted in beneficial ownership |
| Options/RSUs excluded (not vesting within 60 days) | 12,210 options; 10,889 RSUs | Excluded from beneficial ownership due to vesting timing |
| Shares Outstanding (for context) | 238,532,252 | As of Mar 31, 2025; Finger ownership ≈0.07% by calculation |
Governance Assessment
- Committee effectiveness: Finger’s placement on Compensation and Governance aligns with prior committee chair/audit experience, providing relevant oversight on pay and governance practices .
- Independence & attendance: Formally independent; met at least the 75% attendance threshold; participated in a Board with active committee cadence, bolstering investor confidence in oversight rigor .
- Pay structure alignment: Director compensation is predominantly equity-based (~83%), with annual RSU and option grants vesting over one year to promote near-term alignment while maintaining refreshment; no perquisites disclosed beyond standard benefits policy for executives (not applicable to directors) .
- Conflicts/related-party exposure: No related-party transactions disclosed involving Finger; Company’s related-party dealings involve entities controlled by Jerrold and Adam Grossman (Areth; GenesisBPS), not Finger . Compensation Committee disclosed use of independent consultants (Radford Aon; Pay Governance) with no conflicts, supporting high governance quality in pay decisions .
- Hedging/pledging controls: Insider Trading Policy prohibits derivative and hedging transactions; directors and executives prohibited from shorts; the Company notes no standalone hedging policy but prohibitions are embedded in the Insider Trading Policy—mitigating alignment risks. No pledging disclosed for Finger (CEO Adam Grossman disclosed pledging, but not Finger) .
- RED FLAGS: None disclosed for Finger regarding attendance, related-party transactions, hedging/pledging, or Section 16 compliance. Compensation committee interlocks not present in FY2024; independence affirmed .